文献速递慢性静脉疾病

Flebogrif导管机械化学消融治疗大隐静脉反流的前瞻性多中心一年结果

The prospective multicenter study assessing safety and efficacy of mechanochemical ablation with the use of the Flebogrif catheter in patients with great saphenous vein incompetence: One year results.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2026-07-30

POLFLEB研究前瞻性纳入200例大隐静脉反流患者,采用Flebogrif导管非旋转机械化学消融联合3%聚多卡醇泡沫治疗。术后3个月解剖闭塞率95.8%,30天内无严重不良事件,12个月随访未见静脉反流,提示该疗法安全有效。

要点

  • 术后3个月大隐静脉无反流率95.8%,含8.9%部分闭塞但无反流。
  • 术后30天内无严重不良事件报告。
  • 12个月随访全段再通4.4%,但均无反流。

核心结论

  • Flebogrif导管机械化学消融是非热消融大隐静脉的安全且临床有效选择。

研究设计与样本

  • POLFLEB研究为前瞻性多中心临床试验,共纳入200例大隐静脉反流患者,静脉直径4-10 mm。

主要发现

  • 治疗段大隐静脉平均长度43.30 ± 10.30 cm,平均泡沫用量8.69 ± 2.23 mL;87.5%病例泡沫总量不超过10 mL,96%患者不超过12 mL。
  • 术后3个月95.8%治疗段大隐静脉无反流,其中8.9%为部分闭塞但无反流。
  • 术后30天内无严重不良事件报告。
  • 12个月随访中4.4%患者出现全段再通,但90.6%患者无反流。

关键数值与推荐

  • 主要疗效终点为术后3个月大隐静脉解剖闭塞率,结果为95.8%无反流。
  • 主要安全终点为术后30天内严重不良事件,发生率为0。
  • 允许初始消融3个月后追加泡沫硬化治疗。

临床怎么用

  • 对于大隐静脉反流且直径4-10 mm的患者,可考虑Flebogrif导管非旋转机械化学消融联合3%聚多卡醇泡沫作为非热消融选项。
  • 术中泡沫用量多数不超过10 mL,需注意控制总量。

局限性

  • 疗效需通过长期随访研究进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endovenous thermal ablation is recommended as the primary method of managing symptomatic truncal venous reflux. One of the important alternatives to the thermal energy-based methods is mechanochemical ablation; however, its performance and outcomes can significantly differ in relation to the applied technology and sclerosing agent formula. The aim of the study was to prove the safety and efficacy of the nonrotational mechanochemical ablation with polidocanol foam performed by Flebogrif catheter. The study presents 1-year follow-up results. METHODS: The POLFLEB study was a prospective, multicenter clinical trial assessing the safety, efficacy, and feasibility of the Flebogrif catheter (Balton) in a population of patients with incompetent great saphenous vein (GSV; ClinicalTrials.gov NCT04558957). A total of 200 patients were enrolled and treated (GSV diameter, 4-10 mm). In all cases, during nonrotational mechanochemical ablation, 3% polidocanol foam was used, and the patients underwent the clinical and ultrasound-based 12-month follow-up. The primary efficacy end point was the GSV anatomical occlusion rate 3 months after the procedure. The primary safety study end point was the occurrence of serious adverse events up to 30 days after the procedure. According to the study protocol, the additional foam sclerotherapy treatment was allowed 3 months after the initial truncal ablation. RESULTS: The mean length of the treated GSV segment was 43.30 ± 10.30 cm (minimum, 20 cm; maximum, 70 cm), and the mean foam volume used during the procedure was 8.69 ± 2.23 mL (in 87.5% of the treated cases, the foam volume did not exceed 10 mL in total and in 96% of the patients the foam volume not exceeding 12 mL was used). Successful vein obliteration was achieved in all patients, which was confirmed intraoperatively and within 7 days of postoperative ultrasound control. Three months after the treatment, 95.8% of the treated saphenous veins remained without reflux, including 8.9% with partial vein occlusion and no reflux. No serious adverse events were reported within 30 days after the procedure. In the 12-month follow-up, the whole vein reopening was found in 4.4% and in 90.6% of the patients; however, no saphenous vein reflux was noticed. CONCLUSIONS: Mechanochemical ablation by Flebogrif catheter represents the safe and clinically effective option for nonthermal saphenous vein ablation. The efficacy of the method should be confirmed in studies with long-term follow-up.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Zubilewicz T, Urbanek T, Janczak D, et al. The prospective multicenter study assessing safety and efficacy of mechanochemical ablation with the use of the Flebogrif catheter in patients with great saphenous vein incompetence: One year results. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42532411. doi:10.1016/j.jvsv.2026.102584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。